Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Environ Health Perspect ; 132(4): 47002, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38568856

ABSTRACT

BACKGROUND: There is a suite of chemicals, including metals, pesticides, and personal care product compounds, which are commonly detected at high levels in US Center for Disease Control's National Health and Nutrition Examination Survey (NHANES) chemical biomarker screens. Whether these chemicals influence development of breast cancer is not well understood. OBJECTIVES: The objectives were to perform an unbiased concentration-dependent assessment of these chemicals, to quantify differences in cancer-specific genes and pathways, to describe if these differences occur at human population-relevant concentrations, and to specifically test for differences in markers of stemness and cellular plasticity. METHODS: We treated nontumorigenic mammary epithelial cells, MCF10A, with 21 chemicals at four concentrations (25 nM, 250 nM, 2.5µM, and 25µM) for 48 h. We conducted RNA-sequencing for these 408 samples, adapting the plexWell plate-based RNA-sequencing method to analyze differences in gene expression. We calculated gene and biological pathway-specific benchmark concentrations (BMCs) using BMDExpress3, identifying differentially expressed genes and generating the best fit benchmark concentration models for each chemical across all genes. We identified enriched biological processes and pathways for each chemical and tested whether chemical exposures change predicted cell type distributions. We contextualized benchmark concentrations relative to human population biomarker concentrations in NHANES. RESULTS: We detected chemical concentration-dependent differences in gene expression for thousands of genes. Enrichment and cell type distribution analyses showed benchmark concentration responses correlated with differences in breast cancer-related pathways, including induction of basal-like characteristics for some chemicals, including arsenic, lead, copper, and methyl paraben. Comparison of benchmark data to NHANES chemical biomarker (urine or blood) concentrations indicated an overlap between exposure levels and levels sufficient to cause a gene expression response. DISCUSSION: These analyses revealed that many of these 21 chemicals resulted in differences in genes and pathways involved in breast cancer in vitro at human exposure-relevant concentrations. https://doi.org/10.1289/EHP12886.


Subject(s)
Breast Neoplasms , Gene Expression Profiling , Humans , Female , Nutrition Surveys , Breast Neoplasms/chemically induced , Biomarkers , RNA
2.
Environ Res ; 252(Pt 3): 118956, 2024 Jul 01.
Article in English | MEDLINE | ID: mdl-38640990

ABSTRACT

Environmental chemical exposures influence immune system functions, and humans are exposed to a wide range of chemicals, termed the chemical "exposome". A comprehensive, discovery analysis of the associations of multiple chemical families with immune biomarkers is needed. In this study, we tested the associations between environmental chemical concentrations and immune biomarkers. We analyzed the United States cross-sectional National Health and Nutrition Examination Survey (NHANES, 1999-2018). Chemical biomarker concentrations were measured in blood or urine (196 chemicals, 17 chemical families). Immune biomarkers included counts of lymphocytes, neutrophils, monocytes, basophils, eosinophils, red blood cells, white blood cells, and mean corpuscular volume. We conducted separate survey-weighted, multivariable linear regressions of each log2-transformed chemical and immune measure, adjusted for relevant covariates. We accounted for multiple comparisons using a false discovery rate (FDR). Among 45,528 adult participants, the mean age was 45.7 years, 51.4% were female, and 69.3% were Non-Hispanic White. 71 (36.2%) chemicals were associated with at least one of the eight immune biomarkers. The most chemical associations (FDR<0.05) were observed with mean corpuscular volume (36 chemicals) and red blood cell counts (35 chemicals). For example, a doubling in the concentration of cotinine was associated with 0.16 fL (95% CI: 0.15, 0.17; FDR<0.001) increased mean corpuscular volume, and a doubling in the concentration of blood lead was associated with 61,736 increased red blood cells per µL (95% CI: 54,335, 69,138; FDR<0.001). A wide variety of chemicals, such as metals and smoking-related compounds, were highly associated with immune system biomarkers. This environmental chemical-wide association study identified chemicals from multiple families for further toxicological, immunologic, and epidemiological investigation.


Subject(s)
Biomarkers , Environmental Exposure , Humans , Cross-Sectional Studies , Female , Biomarkers/blood , Male , Middle Aged , United States , Adult , Nutrition Surveys , Environmental Pollutants/blood
3.
J Expo Sci Environ Epidemiol ; 33(5): 687-698, 2023 09.
Article in English | MEDLINE | ID: mdl-37718377

ABSTRACT

BACKGROUND: Some hormonally active cancers have low survival rates, but a large proportion of their incidence remains unexplained. Endocrine disrupting chemicals may affect hormone pathways in the pathology of these cancers. OBJECTIVE: To evaluate cross-sectional associations between per- and polyfluoroalkyl substances (PFAS), phenols, and parabens and self-reported previous cancer diagnoses in the National Health and Nutrition Examination Survey (NHANES). METHODS: We extracted concentrations of 7 PFAS and 12 phenols/parabens and self-reported diagnoses of melanoma and cancers of the thyroid, breast, ovary, uterus, and prostate in men and women (≥20 years). Associations between previous cancer diagnoses and an interquartile range increase in exposure biomarkers were evaluated using logistic regression models adjusted for key covariates. We conceptualized race as social construct proxy of structural social factors and examined associations in non-Hispanic Black, Mexican American, and other Hispanic participants separately compared to White participants. RESULTS: Previous melanoma in women was associated with higher PFDE (OR:2.07, 95% CI: 1.25, 3.43), PFNA (OR:1.72, 95% CI: 1.09, 2.73), PFUA (OR:1.76, 95% CI: 1.07, 2.89), BP3 (OR: 1.81, 95% CI: 1.10, 2.96), DCP25 (OR: 2.41, 95% CI: 1.22, 4.76), and DCP24 (OR: 1.85, 95% CI: 1.05, 3.26). Previous ovarian cancer was associated with higher DCP25 (OR: 2.80, 95% CI: 1.08, 7.27), BPA (OR: 1.93, 95% CI: 1.11, 3.35) and BP3 (OR: 1.76, 95% CI: 1.00, 3.09). Previous uterine cancer was associated with increased PFNA (OR: 1.55, 95% CI: 1.03, 2.34), while higher ethyl paraben was inversely associated (OR: 0.31, 95% CI: 0.12, 0.85). Various PFAS were associated with previous ovarian and uterine cancers in White women, while MPAH or BPF was associated with previous breast cancer among non-White women. IMPACT STATEMENT: Biomarkers across all exposure categories (phenols, parabens, and per- and poly- fluoroalkyl substances) were cross-sectionally associated with increased odds of previous melanoma diagnoses in women, and increased odds of previous ovarian cancer was associated with several phenols and parabens. Some associations differed by racial group, which is particularly impactful given the established racial disparities in distributions of exposure to these chemicals. This is the first epidemiological study to investigate exposure to phenols in relation to previous cancer diagnoses, and the first NHANES study to explore racial/ethnic disparities in associations between environmental phenol, paraben, and PFAS exposures and historical cancer diagnosis.


Subject(s)
Breast Neoplasms , Environmental Pollutants , Fluorocarbons , Melanoma , Ovarian Neoplasms , Male , Humans , Female , Phenols , Parabens/analysis , Nutrition Surveys , Cross-Sectional Studies , Biomarkers
4.
Epigenetics ; 17(2): 161-177, 2022.
Article in English | MEDLINE | ID: mdl-33588693

ABSTRACT

Saliva is a widely used biological sample, especially in pediatric research, containing a heterogenous mixture of immune and epithelial cells. Associations of exposure or disease with saliva DNA methylation can be influenced by cell-type proportions. Here, we developed a saliva cell-type DNA methylation reference panel to estimate interindividual cell-type heterogeneity in whole saliva studies. Saliva was collected from 22 children (7-16 years) and sorted into immune and epithelial cells, using size exclusion filtration and magnetic bead sorting. DNA methylation was measured using the Illumina MethylationEPIC BeadChip. We assessed cell-type differences in DNA methylation profiles and tested for enriched biological pathways. Immune and epithelial cells differed at 181,577 (22.8%) DNA methylation sites (t-test p < 6.28 × 10-8). Immune cell hypomethylated sites are mapped to genes enriched for immune pathways (p < 3.2 × 10-5). Epithelial cell hypomethylated sites were enriched for cornification (p = 5.2 × 10-4), a key process for hard palette formation. Saliva immune and epithelial cells have distinct DNA methylation profiles which can drive whole-saliva DNA methylation measures. A primary saliva DNA methylation reference panel, easily implemented with an R package, will allow estimates of cell proportions from whole saliva samples and improve epigenetic epidemiology studies by accounting for measurement heterogeneity by cell-type proportions.


Subject(s)
DNA Methylation , Saliva , Child , CpG Islands , Epidemiologic Studies , Epigenesis, Genetic , Epigenomics , Humans
5.
Toxicology ; 463: 152964, 2021 11.
Article in English | MEDLINE | ID: mdl-34600088

ABSTRACT

Among women, breast cancer is the most prevalent form of cancer worldwide and has the second highest mortality rate of any cancer in the United States. The breast cancer related death rate is 40 % higher in non-Hispanic Black women compared to non-Hispanic White women. The incidence of triple negative breast cancer (TNBC), an aggressive subtype of breast cancer for which there is no targeted therapy, is also approximately three times higher for Black, relative to, White women. The drivers of these differences are poorly understood. Here, we aimed to identify chemical exposures which play a role in breast cancer disparities. Using chemical biomonitoring data from the National Health and Nutrition Examination Survey (NHANES) and biological activity data from the EPA's ToxCast program, we assessed the toxicological profiles of chemicals to which US Black women are disproportionately exposed. We conducted a literature search to identify breast cancer targets in ToxCast to analyze the response of chemicals with exposure disparities in these assays. Forty-three chemical biomarkers are significantly higher in Black women. Investigation of these chemicals in ToxCast resulted in 32,683 assays for analysis, 5172 of which contained nonzero values for the concentration at which the dose-response fitted model reaches the cutoff considered "active". Of these chemicals BPA, PFOS, and thiram are most comprehensively assayed. 2,5-dichlorophenol, 1,4-dichlorobenzene, and methyl and propyl parabens had higher biomarker concentrations in Black women and moderate testing and activity in ToxCast. The distribution of active concentrations for these chemicals in ToxCast assays are comparable to biomarker concentrations in Black women NHANES participants. Through this integrated analysis, we identify that multiple chemicals, including thiram, propylparaben, and p,p' DDE, have disproportionate exposures in Black women and have breast cancer associated biological activity at human exposure relevant doses.


Subject(s)
Black or African American/statistics & numerical data , Breast Neoplasms/epidemiology , Hazardous Substances/toxicity , Health Status Disparities , Biomarkers/metabolism , Environmental Exposure/adverse effects , Female , Humans , Nutrition Surveys , Triple Negative Breast Neoplasms/epidemiology , United States/epidemiology , White People/statistics & numerical data
6.
Environ Health Perspect ; 127(12): 127004, 2019 12.
Article in English | MEDLINE | ID: mdl-31834828

ABSTRACT

BACKGROUND: Billions of dollars are spent on environmental dredging (ED) to remediate contaminated sediments, with one goal being reduced human health risks. However, ED may increase health risks in unanticipated ways, thus potentially reducing net benefits. OBJECTIVES: To assess the ways that ED may increase health risks in unanticipated ways, thus potentially reducing net benefits, we quantitatively assessed a subset of population health benefits and risks of ED, using the 2009-2015 remediation of the Hudson River Polychlorinated Biphenyls (PCBs) Superfund Site as a case study. Three remediation scenarios were evaluated: No Action (NA), Source Control (SC), and ED. METHODS: We quantified health benefits for each scenario from reduced PCB levels in Hudson River fish, and health risks from ED operations due to increased inhalation exposures to PCBs and fine particulate matter (PM2.5), using disability-adjusted life years (DALYs) as a common metric. Occupational health risks were also considered in a separate sensitivity analysis. Estimates of population-level benefits and risks included Monte Carlo simulation-based uncertainty analysis. RESULTS: Under NA, fish consumption would result in an estimated health burden of 112 DALYs, and ED would lead to a reduction of 15 DALYs in excess of SC. ED operations were estimated to induce a total burden of 33 DALYs, dominated by PM2.5 impacts from rail transport emissions (32 DALYs). Including uncertainty, the net health benefit of ED ranged from -138 to +1,326 avoided DALYs (90% confidence), with a median of -11 avoided DALYs. CONCLUSIONS: For the considered impacts, ED in the Hudson River might not have led to an overall net positive human health impact. The benefits and risks of ED, however, have different degrees of uncertainty and involve different populations. Reducing long-distance transport of dredged sediment is a priority. This comparative approach could be used prospectively to better determine trade-offs involved in different remediation scenarios and to improve remediation design to maximize benefits while minimizing risks. https://doi.org/10.1289/EHP5034.


Subject(s)
Diet/statistics & numerical data , Environmental Restoration and Remediation , Fishes , Inhalation Exposure/statistics & numerical data , Seafood/statistics & numerical data , Water Pollutants, Chemical/analysis , Animals , Geologic Sediments/chemistry , Humans
7.
Antimicrob Agents Chemother ; 60(3): 1274-82, 2015 Dec 14.
Article in English | MEDLINE | ID: mdl-26666942

ABSTRACT

Artemether-lumefantrine is a first-line regimen for the treatment of uncomplicated malaria during the second and third trimesters of pregnancy. Previous studies have reported changes in the pharmacokinetics and clinical outcomes following treatment with artemether-lumefantrine in pregnant women compared to nonpregnant adults; however, the results are inconclusive. We conducted a study in rural Uganda to compare the pharmacokinetics of artemether-lumefantrine and the treatment responses between 30 pregnant women and 30 nonpregnant adults with uncomplicated Plasmodium falciparum malaria. All participants were uninfected with HIV, treated with a six-dose regimen of artemether-lumefantrine, and monitored clinically for 42 days. The pharmacokinetics of artemether, its metabolite dihydroartemisinin, and lumefantrine were evaluated for 21 days following treatment. We found no significant differences in the overall pharmacokinetics of artemether, dihydroartemisinin, or lumefantrine in a direct comparison of pregnant women to nonpregnant adults, except for a statistically significant but small difference in the terminal elimination half-lives of both dihydroartemisinin and lumefantrine. There were seven PCR-confirmed reinfections (5 pregnant and 2 nonpregnant participants). The observation of a shorter terminal half-life for lumefantrine may have contributed to a higher frequency of reinfection or a shorter posttreatment prophylactic period in pregnant women than in nonpregnant adults. While the comparable overall pharmacokinetic exposure is reassuring, studies are needed to further optimize antimalarial efficacy in pregnant women, particularly in high-transmission settings and because of emerging drug resistance. (This study is registered at ClinicalTrials.gov under registration no. NCT01717885.).


Subject(s)
Antimalarials/pharmacokinetics , Artemisinins/pharmacokinetics , Ethanolamines/pharmacokinetics , Fluorenes/pharmacokinetics , Malaria, Falciparum/drug therapy , Pregnancy Complications, Parasitic/drug therapy , Adolescent , Adult , Antimalarials/adverse effects , Antimalarials/therapeutic use , Artemether , Artemisinins/adverse effects , Artemisinins/therapeutic use , Cohort Studies , Drug Therapy, Combination , Ethanolamines/adverse effects , Ethanolamines/therapeutic use , Female , Fluorenes/adverse effects , Fluorenes/therapeutic use , Humans , Lumefantrine , Middle Aged , Pregnancy , Prospective Studies , Treatment Outcome , Uganda , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...